

PRESSE RELEASE

Lyon, June 2nd, 2021



ADOCIA

innovative medicine
for everyone, everywhere

ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021)

7.30am CEST- ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides, today announced an oral presentation on the bi-hormonal treatment M1Pram (ADO09) at the 14th International Conference on Advanced Technologies and Treatments for Diabetes ([ATTD 2021](#)), which will be held June 2-5, 2021 as a virtual event.

You will find below detailed information on the presentation:

- Session: **0060 - Oral Presentation 02**
Date & Time: Wednesday 2 June 7.45pm – 7.55pm CEST
Room: **Hall B**
Oral Presentation: [#498 - ADO09, A CO-FORMULATION OF PRAMLINTIDE AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE \(PPG\) VERSUS INSULIN ASPART IN TYPE 1 DIABETES \(T1D\)](#)
Duration: 10 min

About ATTD

[ATTD](#) a scientific program that brings together renowned international experts to discuss major advances in diabetes treatments, technological innovations and present the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and more.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes, obesity and metabolic diseases. In the diabetes field, Adocia's portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products and several pre-clinical products. The proprietary BioChaperone®

technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.

Adocia's clinical pipeline includes four novel insulin formulations for prandial treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone® Combo) and one combination of a prandial insulin with amylin analog pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia.

Adocia preclinical pipeline includes bi-hormonal combinations for diabetes treatment: two combinations of rapid acting insulin analogs and Pramlintide (BioChaperone® Lispro Pram and BioChaperone® Aspart Pram), a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In addition, there are two bi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® Glucagon Exenatide) and a combination of pramlintide and exenatide (PramExe).

Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes. The first patent application supporting this program has been filed.

Contact Adocia

Adocia

Gérard Soula

CEO

contactinvestisseurs@adocia.com

Ph: +33 4 72 610 610

www.adocia.com

MC Services AG

Adocia Press Relations Europe

Raimund Gabriel

Managing Partner

adocia@mc-services.eu

Ph: +49 89 210 228 0

The Ruth Group

**Adocia Investor Relations
USA**

James Salierno

Vice-President

jsalierno@theruthgroup.com

Ph.: +1 646 536 7035



European **Rising Tech**
LABEL



Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Universal Registration Document filed with the French Autorité des marchés financiers on April 20, 2021 (a copy of which is available at www.adocia.com) and to the development of economic

conditions financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.